Skip to main content

Table 3 Time-Course Changes of Reflux Symptom Scoresa between the Two Groups

From: Efficacy of a high-dose proton pump inhibitor in patients with gastroesophageal reflux disease: a single center, randomized, open-label trial

 

Standard-dose groupb (n = 35)

High-dose groupc (n = 38)

P-value

n

Baseline

4 week (△)

8 week (△)

n

Baseline

4 week (△)

8 week (△)

Total symptoms

35

4.46 ± 2.76

2.09 ± 1.96 (−2.37 ± 1.70)

1.83 ± 1.79 (− 2.63 ± 1.78)

38

4.76 ± 2.01

0.92 ± 1.42 (−3.84 ± 1.98)

0.89 ± 1.37 (−3.87 ± 1.85)

< 0.001

Typical symptomsd

25

2.56 ± 1.12

1.16 ± 1.34 (− 1.40 ± 1.26)

0.80 ± 0.91 (− 1.76 ± 0.83)

29

2.69 ± 1.00

0.28 ± 0.60 (− 2.41 ± 1.24)

0.24 ± 0.44 (− 2.45 ± 1.09)

0.004

Heartburn

21

2.14 ± 0.73

0.90 ± 1.04 (− 1.24 ± 0.83)

0.76 ± 0.89 (− 1.38 ± 0.74)

19

2.26 ± 0.56

0.26 ± 0.65 (− 2.00 ± 0.82)

0.21 ± 0.42 (− 2.05 ± 0.71)

0.004

Acid regurgitation

11

1.73 ± 0.65

0.36 ± 0.51 (− 1.36 ± 0.51)

0.36 ± 0.51 (− 1.36 ± 0.51)

16

2.19 ± 0.54

0.19 ± 0.40 (− 2.00 ± 0.63)

0.19 ± 0.40 (− 2.00 ± 0.52)

0.005

Atypical symptomse

27

3.41 ± 1.93

1.85 ± 1.51 (− 1.56 ± 1.19)

1.56 ± 1.28 (− 1.85 ± 1.35)

34

3.03 ± 1.14

0.79 ± 1.23 (− 2.24 ± 1.28)

0.79 ± 1.27 (− 2.24 ± 1.26)

0.079

Chest pain

7

2.29 ± 0.49

1.14 ± 0.90 (− 1.14 ± 0.90)

0.71 ± 0.76 (− 1.57 ± 0.54)

11

2.27 ± 0.65

0.91 ± 0.94 (− 1.36 ± 0.92)

0.82 ± 1.08 (− 1.45 ± 0.93)

0.692

Cough

6

2.17 ± 0.75

1.50 ± 1.23 (− 0.67 ± 0.82)

1.33 ± 1.03 (− 0.83 ± 0.75)

8

2.25 ± 0.71

0.38 ± 0.74 (− 1.87 ± 1.13)

0.38 ± 0.52 (− 1.87 ± 1.13)

0.044

Globus

20

2.30 ± 0.66

1.35 ± 0.75 (− 0.95 ± 0.61)

1.20 ± 0.77 (− 1.10 ± 0.72)

17

2.47 ± 0.51

0.47 ± 0.80 (− 2.00 ± 0.79)

0.53 ± 0.80 (− 1.94 ± 0.75)

< 0.001

Wheezing

1

2.00 ± 0.00

1.00 (− 1.00)

1.00 (− 1.00)

0

–

–

–

–

Laryngopharyngitis

0

–

–

–

0

–

–

–

–

Hoarseness

2

2.00 ± 0.00

0.50 ± 0.71 (−1.50 ± 0.71)

0.50 ± 0.71 (− 1.50 ± 0.71)

4

3.00 ± 0.00

1.50 ± 1.29 (− 1.50 ± 1.29)

1.50 ± 1.29 (− 1.50 ± 1.29)

1.000

Belching

5

2.20 ± 0.45

0.80 ± 1.01 (− 1.40 ± 0.89)

0.60 ± 0.89 (− 1.60 ± 0.55)

3

1.33 ± 0.58

0.00 ± 0.00 (− 1.33 ± 0.58)

0.00 ± 0.00 (− 1.33 ± 0.58)

0.822

Dysphagia

0

–

–

–

1

2.00 ± 0.00

0.00 (− 2.00)

0.00 (− 2.00)

–

  1. P-values were calculated using repeated measure ANOVA
  2. Values are presented as mean ± standard deviation
  3. aSymptom score was the mean value of the score sum of the 5-graded Likert scale questionnaire
  4. bStandard-dose group was treated as rabeprazole 20 mg once daily
  5. cHigh-dose group was treated as rabeprazole 20 mg twice daily
  6. dTypical symptoms were defined as heartburn and regurgitation
  7. eAtypical symptoms were defined as chest pain, cough, globus, wheezing, laryngopharyngitis, hoarseness, belching, and dysphagia
  8. Bold style indicates statistical significance
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us